Tinaqq0805 (Talk | contribs) |
Tinaqq0805 (Talk | contribs) |
||
Line 3: | Line 3: | ||
<div class="col-md-12 column" style="width:100%;height:250px;background-size:contain;0px -100px; background-image:url(https://static.igem.org/mediawiki/2018/6/66/T--NUDT_CHINA--banner_project_design.jpg);background-repeat:no-repeat;"> | <div class="col-md-12 column" style="width:100%;height:250px;background-size:contain;0px -100px; background-image:url(https://static.igem.org/mediawiki/2018/6/66/T--NUDT_CHINA--banner_project_design.jpg);background-repeat:no-repeat;"> | ||
<p style="font-size:36px;margin: 0 0%;padding: 5% 0 0 10%;color: white;">Designed Protein Degradation Method Based on</p> | <p style="font-size:36px;margin: 0 0%;padding: 5% 0 0 10%;color: white;">Designed Protein Degradation Method Based on</p> | ||
− | <p style="font-size:36px;margin: 0 0%;padding: 0 0 0 10%;color: white;">Trim21 And Nanobody -- Design</p> | + | <p style="font-size:36px;margin: 0 0%;padding: 0 0 0 10%;color: white;">Trim21 And Nanobody -- Design</p> |
</div> | </div> | ||
Revision as of 01:53, 18 October 2018
Designed Protein Degradation Method Based on
Trim21 And Nanobody -- Design
PR PREDATOR-An improved protein degradation method based on ectopic expression of TRIM21 and recombinant antibody
Design: By combining TRIM-AWAY strategy and ectopic expression of nanobody, we developed an improved method for degrading endogenous proteins in mammalian cells, named as PR PREDATOR. Two major barriers occur when attempting to selectively degrade endogenous proteins, one of which is the specificity, and the second is a powerful degradation mechanism to rely on. To address the specificity concern, we managed to use existing nanobody technique to achieve highly specific target recognition. By scanning existing patent files and literature reports, we built a data sheet with all available nanobodies and their target proteins enclosed. This data sheet can provide a sound basis for standardization of these nanobodies for further usage. The nanobodies are then fused with human IgG-Fc domain to bind Trim21, a powerful E3 ubiquitin-protein ligase we chose to mediate the degradation of target protein through proteasome. The plasmid expressing the PR PREDATOR system was constructed by putting the coding regions of HA-Trim21 and nanobody-IgG Fc under CMV promoter. The HA-Trim21 and nanobody-IgG Fc regions were separated by P2A sequence to achieve bicistronic expression (Figure 1a). We introduced the Recombinant plasmids into cells, nanobody specific binds to proteins with high affinity, forming tight complexes. Trim21 binds with high affinity to the Fc domain of antibodies and TRIM21 recruits the ubiquitin-proteasome system to antibody-bound complex, leading to their destruction.
Figure1. Schematic representation of the degration process of our scheme
Figure2.Workflow for our PR PREDATOR
This is the sign of the famous game!
As a Proof of concept of our idea, we constructed GFP nanobody sequence into our PR PREDATOR system.We choose GFP because the results of experiment is visible. For a more complicated demonstration, the receptor tyrosine-protein kinase erbB-3 is selected. This protein is able to bind and form the heterodimerization with proteins from the erbB family, which is highly involved in proliferation and metastasis of cancer cells, including breast cancer, pancreatic adenocarcinoma and so on. It’s also implicated in chemotherapeutic resistance to NSCLC (non-small cell lung cancer) and another cancers through multiple signaling pathways, such as PI-3K/AKT and Jak/Stat signaling pathways. It has been proved that the downregulation of erbB-3 slows down the process several cancers. The most important reason of selecting erbB3 as our demonstration, is that many antibodies of erbB3 have been used in clinical trials for therapy in many kinds of cancer patients. Such as MM-121, AMG 888(U3-1287), TK-A3, TK-A4, AV-203, LJM716, MEHD7945A, MEHD7945A, MM-111 and MM-141. In our demonstration, the erbB-3 scFv antibody sequence would be expressed along with trim21 in MCF7 cells and directly functions on erbB-3 to bring down its containment and inhibit MCF7 cells proliferation.